“We are pleased with these positive outcomes of the initial preclinical studies in our CMV vaccine program, demonstrating our AI-Immunology™ platform’s ability to identify novel antigens to ...

No approved CMV vaccine exists today COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ ...

Design: A convenient sample of urine specimens from asymptomatic newborns were subjected to CMV PCR. Positive results were validated by urine tube culture and by determination of serum CMV IgM ...

No approved CMV vaccine exists today COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in ...

No approved CMV vaccine exists today COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ ...

About cytomegalovirus (CMV) About 1 in 200 babies is born with congenital CMV infection. About 1 in 5 babies with the infection will have congenital disabilities or other long-term health problems.

and higher percentages were ANA positive at baseline compared with non-transitioned relatives (p<0.0001, table 1). Controls in this study had higher seropositivity and antibody levels against CMV and ...